British-Swedish multinational pharmaceutical and biotechnology company developing treatments for cancer, cardiovascular, and respiratory diseases.
Profile & Fundamentals
AstraZeneca: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
AstraZeneca Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Company profile record
AstraZeneca PLC
Common Stock · Health Care · Pharmaceuticals
Company
- Company / asset
- AstraZeneca PLC
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Pharmaceuticals
- HQ
- 🇬🇧 United Kingdom
- Head office
- 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
Leadership & scale
- Chief executive
- Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.
- CEO year born
- 1959
- Full-time employees
- 96.1K
- Fiscal year end
- December
- IPO date
- 1993-05-12
Fundamentals snapshot
- Market Cap
- GBP 186.5B
- P/E
- 23.6x
- Revenue (Q2 26)
- USD 15.3B
- Profit (Q2 26)
- USD 2.5B
- Dividend Yield
- 2.0%
- Revenue (FY 25)
- USD 58.7B
- Shares in public float
- 1.5B
- Insider ownership
- 0.05%
Reporting & identifiers
- Symbol
- AZN.LSE
- Listing
- 🇬🇧 United Kingdom | Dividend Tax: 0%
- Ticker Currency
- GBX
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- GB0009895292
- Asset ID
- equity_857469cd-9a16-50e9-a787-c28db4d35a54
Ownership
Shares Outstanding
Latest: 1.6B | Max: 1.6B | Min: 1.3B
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
98.90%
1.5B latest reported shares
Insider Ownership
0.05%
Latest reported insider stake
Short Float
4.26%
Latest reported short interest / float
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 1,267,000,000 |
| 2018-01-01 | 1,267,000,000 |
| 2019-01-01 | 1,312,000,000 |
| 2020-01-01 | 1,313,000,000 |
| 2021-01-01 | 1,547,000,000 |
| 2022-01-01 | 1,559,000,000 |
| 2023-01-01 | 1,561,000,000 |
| 2024-01-01 | 1,562,000,000 |
| 2025-01-01 | 1,563,000,000 |
| 2026-01-01 | 1,560,000,000 |
Top Holders
Available reported ownership records.
No reported records are available in this preview.
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
AstraZeneca's financial trajectory highlights a strong underlying commercial engine transitioning toward high-margin specialty medicine. Fiscal 2025 revenue rose 11% to USD 58.7 billion, and net income reached USD 10.22 billion, supported by robust oncology and rare-disease demand. Trailing twelve-month revenue expanded past USD 61 billion by mid-2026, demonstrating that double-digit volume growth in key cancer therapies has effectively cushioned early pricing pressures on mature cardiovascular lines. However, the composition of these earnings demands careful interpretation. While management's core operating metrics showcase double-digit expansion, reported statutory earnings reflect substantial charges for intangible asset amortization and legal provisions. Free cash flow generation of USD 8.43 billion remains solid, but cash conversion lags adjusted accounting profit due to ongoing launch investments and working capital movements.
AstraZeneca's financial trajectory highlights a strong underlying commercial engine transitioning toward high-margin specialty medicine. Fiscal 2025 revenue rose 11% to USD 58.7 billion, and net income reached USD 10.22 billion, supported by robust oncology and rare-disease demand. Trailing twelve-month revenue expanded past USD 61 billion by mid-2026, demonstrating that double-digit volume growth in key cancer therapies has effectively cushioned early pricing pressures on mature cardiovascular lines. However, the composition of these earnings demands careful interpretation. While management's core operating metrics showcase double-digit expansion, reported statutory earnings reflect substantial charges for intangible asset amortization and legal provisions. Free cash flow generation of USD 8.43 billion remains solid, but cash conversion lags adjusted accounting profit due to ongoing launch investments and working capital movements.
Revenue, Net Income, and Free Cash Flow
Latest: USD 58.7B | Max: USD 58.7B | Min: USD 109.9M
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 28x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Profitability trends showcase meaningful structural expansion as the product portfolio shifts toward advanced biologic therapies. Gross margins widened to 81.9% in fiscal 2025, driven by an increasing mix of high-value oncology and rare-disease medicines that carry superior pricing power. Operating margins reached 23.4%, held in check primarily by deliberate increases in late-stage clinical development expenditure rather than underlying operational inefficiency. Sustaining margin expansion toward management's targeted mid-thirties percentage range will face intermediate friction. As patent expirations on Farxiga erode high-margin metabolic sales and statutory US price negotiation caps realized pricing, product mix will encounter temporary drag. Long-term margin progression depends on whether commercial launch volumes can generate sufficient operating leverage across existing sales infrastructure to absorb fixed research overhead.
Profitability trends showcase meaningful structural expansion as the product portfolio shifts toward advanced biologic therapies. Gross margins widened to 81.9% in fiscal 2025, driven by an increasing mix of high-value oncology and rare-disease medicines that carry superior pricing power. Operating margins reached 23.4%, held in check primarily by deliberate increases in late-stage clinical development expenditure rather than underlying operational inefficiency. Sustaining margin expansion toward management's targeted mid-thirties percentage range will face intermediate friction. As patent expirations on Farxiga erode high-margin metabolic sales and statutory US price negotiation caps realized pricing, product mix will encounter temporary drag. Long-term margin progression depends on whether commercial launch volumes can generate sufficient operating leverage across existing sales infrastructure to absorb fixed research overhead.
Profitability Margins
Latest: 81.9% | Max: 81.9% | Min: 0.3%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
81.9%
Gross profit / revenue
Operating Margin
23.4%
Operating income / revenue
Net Margin
17.4%
Net income / revenue
FCF Margin
14.8%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2016-12-31 | 20,922,437,000 | 3,182,663,000 | 1,831,000,000 |
| 2017-12-31 | 23,451,187,000 | 3,132,740,000 | 1,958,000,000 |
| 2018-12-31 | 20,985,198,000 | 2,047,221,000 | 1,247,000,000 |
| 2019-12-31 | 24,499,285,573 | 1,341,311,771 | 509,000,000 |
| 2020-12-31 | 29,270,095,288 | 3,390,129,177 | 2,193,000,000 |
| 2021-12-31 | 37,107,249,357 | 109,851,502 | 3,763,000,000 |
| 2022-12-31 | 44,253,418,000 | 3,280,766,000 | 7,237,000,000 |
| 2023-12-31 | 46,583,069,000 | 6,055,362,000 | 6,567,000,000 |
| 2024-12-31 | 52,943,888,000 | 6,888,100,000 | 7,275,000,000 |
| 2025-12-31 | 58,739,000,000 | 10,225,000,000 | 8,670,000,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 28.28 | Trailing four quarters |
| 2024-12-31 | 29.09 | Trailing four quarters |
| 2023-12-31 | 35.19 | Trailing four quarters |
| 2022-12-31 | 64.5 | Annual net income |
| 2021-12-31 | 1,649.82 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2016-12-31 | 75.78 | 15.49 | 15.21 | 8.75 |
| 2017-12-31 | 74.11 | 15.45 | 13.36 | 8.35 |
| 2018-12-31 | 71.78 | 8.31 | 9.76 | 5.94 |
| 2019-12-31 | 72.35 | 11.51 | 5.47 | 2.08 |
| 2020-12-31 | 74.01 | 16.98 | 11.58 | 7.49 |
| 2021-12-31 | 60.9 | 7.57 | 0.3 | 10.14 |
| 2022-12-31 | 63.36 | 11.41 | 7.41 | 16.35 |
| 2023-12-31 | 73.95 | 20.54 | 13 | 14.1 |
| 2024-12-31 | 74.98 | 23.65 | 13.01 | 13.74 |
| 2025-12-31 | 81.9 | 23.4 | 17.41 | 14.76 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-22.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.